Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director · Chief Executive Officer | January 23, 2026 | January 27, 2026 |
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date January 23, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,236,409 |
Reported balance
After 2026-01-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 79,000 · Balance 2,236,409 F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2: Includes the unvested portion of the Reporting Person's RSU grants. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.13 · Expires 2036-01-22 | Direct | 315,000 |
Reported balance
After 2026-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-23 · Grant · Acquired 315,000 · Balance 315,000 F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
F2: Includes the unvested portion of the Reporting Person's RSU grants.
F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
IDEAYA Biosciences, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16 | Direct | 20,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2019 Filed Dec 20, 2019 00:09 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001567619-19-023460 · doc1.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2029-09-23 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 18:03 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 2,380 | $7.95 | $18,928.14 |
DisclosureSEC source: 0001209191-19-035453 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rosen Family Trust Disclosed balance after: 3,023,139 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.88 to $8.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 18:03 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 19,358 | $7.93 | $153,416.02 |
DisclosureSEC source: 0001209191-19-035453 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rosen Family Trust Disclosed balance after: 3,020,759 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.73 to $8.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 14:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 25,770 | $7.75 | $199,825.73 |
DisclosureSEC source: 0001209191-19-034622 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The RosenFamily Trust Disclosed balance after: 3,001,401 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.42 to $8.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 14:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 15,770 | $8.16 | $128,749.43 |
DisclosureSEC source: 0001209191-19-034622 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rosen Family Trust Disclosed balance after: 2,975,631 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 17:59 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001209191-19-004477 · doc4.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-01-15 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 16, 2019, subject to the Reporting Person's continued service to the Company. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 17:25 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 10,650 | $15.48 | $164,844.96 |
DisclosureSEC source: 0001209191-18-048775 · doc4.xml · nonDerivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,959,861 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 17:25 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 800 | $14.92 | $11,937.04 |
DisclosureSEC source: 0001209191-18-048775 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,949,211 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 17:25 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 7,157 | $14.48 | $103,649.11 |
DisclosureSEC source: 0001209191-18-048775 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,948,411 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 24, 2018 Filed Aug 24, 2018 21:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 4,954 | $13.40 | $66,363.29 |
DisclosureSEC source: 0001209191-18-048417 · doc4.xml · nonDerivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,941,254 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.20 to $13.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 21:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 2,133 | $13.50 | $28,800.19 |
DisclosureSEC source: 0001209191-18-048417 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,936,300 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.27 to $13.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 21:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 2,202 | $13.52 | $29,776.55 |
DisclosureSEC source: 0001209191-18-048417 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,934,167 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 21, 2018 Filed Aug 21, 2018 23:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 2,790 | $13.20 | $36,828.00 |
DisclosureSEC source: 0001209191-18-047851 · doc4.xml · nonDerivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,931,965 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.12 to $13.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 23:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 1,301 | $13.21 | $17,186.21 |
DisclosureSEC source: 0001209191-18-047851 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,929,175 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.07 to $13.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 23:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 4,800 | $13.27 | $63,712.80 |
DisclosureSEC source: 0001209191-18-047851 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,927,874 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.20 to $13.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 8,932 | $12.95 | $115,648.86 |
DisclosureSEC source: 0001209191-18-047133 · doc4.xml · nonDerivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,923,074 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 13,300 | $12.57 | $167,239.52 |
DisclosureSEC source: 0001209191-18-047133 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,914,142 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.33 to $13.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 6,169 | $12.36 | $76,238.97 |
DisclosureSEC source: 0001209191-18-047133 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,900,842 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 13, 2018 Filed Aug 13, 2018 21:38 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 3,279 | $11.75 | $38,534.15 |
DisclosureSEC source: 0001209191-18-046475 · doc4.xml · nonDerivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,894,673 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.54 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 21:38 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 2,550 | $11.94 | $30,450.57 |
DisclosureSEC source: 0001209191-18-046475 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,891,394 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.86 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 21:38 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 4,100 | $11.92 | $48,869.13 |
DisclosureSEC source: 0001209191-18-046475 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,888,844 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.41 to $12.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries C Convertible Preferred Stock · Derivative | 82,966 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007985 · doc4.xml · derivative · entry 6 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 82,966 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F5 · derivative.underlying_shares: Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries B Convertible Preferred Stock · Derivative | 125,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007985 · doc4.xml · derivative · entry 5 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 125,012 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries A Convertible Preferred Stock · Derivative | 2,267,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007985 · doc4.xml · derivative · entry 4 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 2,267,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 66,666 | $15.00 | $999,990.00 |
DisclosureSEC source: 0000899243-18-007985 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,884,744 F3 · shares: Represents shares purchased in the Issuer's initial public offering. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionCommon Stock | 2,475,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007985 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,818,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.